With a low turnover of shares. Small market cap, and a interesting drug in trial to slow Alzheimer's disease this could have the potential of a blockbuster share to own. Pepinemab is so far well tolerated in the small trial of 50 patients, and should reach its one year conclusion of trials in June. Then potential around another …
Vaccinex looking positive.
GLOBAL RISK FUND 